These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19749354)

  • 1. Influence of 3'-azido-2',3'-dideoxyguanosine treatment on telomere length in human telomerase-immortalized human fibroblast cells.
    Kurashina Y; Liu X; Kato C; Inoue N; Saneyoshi M; Yamaguchi T
    Nucleic Acids Symp Ser (Oxf); 2009; (53):249-50. PubMed ID: 19749354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of 3'-azido-2',3'-dideoxyguanosine treatment on amounts of TERT and POT1 in human HL60 cells.
    Liu X; Ogawara T; Kurashina Y; Saneyoshi M; Yamaguchi T
    Nucleic Acids Symp Ser (Oxf); 2008; (52):491-2. PubMed ID: 18776468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomere shortening in human HL60 cells by treatment with 3'-azido-2',3'-dideoxynucleosides and telomerase inhibition by their 5'-triphosphates.
    Liu X; Inomata M; Ogawara T; Saneyoshi M; Yamaguchi T
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):1067-71. PubMed ID: 18058538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase inhibition by 3'-azido-2', 3'-dideoxynucleoside 5'-triphosphates and telomere shortening in human cultured cells by the corresponding nucleosides.
    Yamaguchi T; Liu X; Ogawara T; Inomata M; Saneyoshi M
    Nucleic Acids Symp Ser (Oxf); 2006; (50):271-2. PubMed ID: 17150922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-Azido-2',3'-dideoxynucleoside 5'-triphosphates inhibit telomerase activity in vitro, and the corresponding nucleosides cause telomere shortening in human HL60 cells.
    Liu X; Takahashi H; Harada Y; Ogawara T; Ogimura Y; Mizushina Y; Saneyoshi M; Yamaguchi T
    Nucleic Acids Res; 2007; 35(21):7140-9. PubMed ID: 17942424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of nucleoside analogue treatment on telomere length and TRF2 amount in human HL60 cells.
    Liu X; Liu J; Ogawara T; Kurashina Y; Yashi R; Saneyoshi M; Yamaguchi T
    Nucleic Acids Symp Ser (Oxf); 2007; (51):253-4. PubMed ID: 18029682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to senescence induction and telomere shortening by a G-quadruplex ligand inhibitor of telomerase.
    Gomez D; Aouali N; Renaud A; Douarre C; Shin-Ya K; Tazi J; Martinez S; Trentesaux C; Morjani H; Riou JF
    Cancer Res; 2003 Oct; 63(19):6149-53. PubMed ID: 14559794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomere shortening in human HL60 cells by treatment with deoxyguanosine analogs.
    Yamaguchi T; Takahashi H; Harada Y; Yoshikawa M; Iyono S; Inomata M; Maruyama T; Saneyoshi M
    Nucleic Acids Symp Ser (Oxf); 2004; (48):187-8. PubMed ID: 17150541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of telomerase modulation in human hematopoietic progenitor cells.
    Zimmermann S; Glaser S; Ketteler R; Waller CF; Klingmüller U; Martens UM
    Stem Cells; 2004; 22(5):741-9. PubMed ID: 15342938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression and regulation in H2O2-induced premature senescence of human foreskin fibroblasts expressing or not telomerase.
    de Magalhães JP; Chainiaux F; de Longueville F; Mainfroid V; Migeot V; Marcq L; Remacle J; Salmon M; Toussaint O
    Exp Gerontol; 2004 Sep; 39(9):1379-89. PubMed ID: 15489061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss.
    Ji HJ; Rha SY; Jeung HC; Yang SH; An SW; Chung HC
    Breast Cancer Res Treat; 2005 Oct; 93(3):227-36. PubMed ID: 16132531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells.
    Binz N; Shalaby T; Rivera P; Shin-ya K; Grotzer MA
    Eur J Cancer; 2005 Dec; 41(18):2873-81. PubMed ID: 16253503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells.
    de Souza Nascimento P; Alves G; Fiedler W
    Oncol Rep; 2006 Aug; 16(2):423-8. PubMed ID: 16820926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomere dynamics in cells with introduced telomerase: a rapid assay for telomerase activity on telomeres.
    McChesney PA; Aisner DL; Frank BC; Wright WE; Shay JW
    Mol Cell Biol Res Commun; 2000 May; 3(5):312-8. PubMed ID: 10964756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic induces telomerase expression and maintains telomere length in human cord blood cells.
    Ferrario D; Collotta A; Carfi M; Bowe G; Vahter M; Hartung T; Gribaldo L
    Toxicology; 2009 Jun; 260(1-3):132-41. PubMed ID: 19464579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
    Kelland LR
    Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cells.
    Zhang RG; Zhang RP; Wang XW; Xie H
    Cell Res; 2002 Mar; 12(1):55-62. PubMed ID: 11942411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
    Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
    Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomerase inhibitors in cancer therapy: current status and future directions.
    Incles CM; Schultes CM; Neidle S
    Curr Opin Investig Drugs; 2003 Jun; 4(6):675-85. PubMed ID: 12901225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters.
    Atkinson SP; Hoare SF; Glasspool RM; Keith WN
    Cancer Res; 2005 Sep; 65(17):7585-90. PubMed ID: 16140922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.